AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33665728
Drug: WM (bioequivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WM (bioequivalent formulation)
Trial: 32151851
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
Trial: 34755388
Drug: Bayesian group-sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian group-sequential trial design utilizing Multisource Exchangeability Models
Trial: 34755388
Drug: Traditional group-sequential
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional group-sequential design
Trial: 32404056
Drug: 2 L‐PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L‐PEG solutions with 1 L GT liquids
Trial: 32404056
Drug: 2 L‐PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L‐PEG solutions only
Trial: 34732695
Drug: Overt SSRI
RxNorm normalized name: Wal-vert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overt SSRI treatment with escitalopram 20 mg
Trial: 34732695
Drug: Covert SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covert SSRI treatment with escitalopram 20 mg
Trial: 34732695
Drug: Overt SSRI
RxNorm normalized name: Wal-vert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overt SSRI treatment
Trial: 34732695
Drug: Covert SSRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Covert SSRI treatment
Trial: 32041601
Drug: Ensifentrine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 0.75 mg
Trial: 32041601
Drug: Ensifentrine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 1.5 mg
Trial: 32041601
Drug: Ensifentrine 3
RxNorm normalized name: ENSIFENTRINE 3MG/2.5ML INHL SUSP AMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 3 mg
Trial: 32041601
Drug: Ensifentrine 6
RxNorm normalized name: Ensifentrine
DrugBank: Ensifentrine (DB16157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine 6 mg
Trial: 32041601
Drug: Ensifentrine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensifentrine (all doses)
Trial: 32885518
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (RT) intervention
Trial: 33499668
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy with rate/rhythm control agents
Trial: 32153038
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Occlusal Splint and Counselling (OSCS)
Trial: 32813887
Drug: GRAZAX® (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAZAX® (sublingual immunotherapy) for 2 years
Trial: 35084724
Drug: Salbutamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol plus budesonide nebulizer (budesonide 0.5 mg nebulized three times for 20 minutes)
Trial: 32332464
Drug: Active placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo, midazolam 0.045 mg/kg
Trial: 34031723
Drug: Dual autonomic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual autonomic blockade (DAB) with 0.04 mg/kg atropine and 0.2 mg/kg metoprolol
Trial: 36449873
Drug: Macrophage-activating gel
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrophage-activating gel
Trial: 33045675
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (400 mcg/day)
Trial: 33357708
Drug: APS pretreatment
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APS pretreatment (0.6 g/L)
Trial: 35983959
Drug: Active THC
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active THC cigarette (26.25 mg/2.7% THC)
Trial: 33242457
Drug: Nevirapine treatment
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine treatment
Trial: 35351134
Drug: Biocan DHPPi+L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocan DHPPi+L (Bioveta, Czech)
Trial: 33683065
Drug: Interferon gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma (IFN‐γ) 500,000 IU administered subcutaneously, daily for 5 days
Trial: 33683065
Drug: Complex therapy
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex therapy of the disease (control group not explicitly mentioned)
Trial: 35810063
Drug: Quadrivalent subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent subunit influenza vaccine (single dose, with a boosting dose at day 28 for children aged 3–8 years)
Trial: 35810063
Drug: Split‐virion influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split‐virion influenza vaccine (control group)
Trial: 35734824
Drug: Precision-medicine approach
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision-medicine approach (comprehensive diagnostic workup and pharmacological treatment specific for the underlying cause)
Trial: 35734824
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (routine diagnostic workup and standard medical treatment for acute coronary syndrome)
Trial: 35734824
Drug: Precision-medicine approach
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision-medicine approach
Trial: 33802219
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (DS) containing Octacosanol (20 mg) and vitamin K2 (45 µg)
Trial: 35253599
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (forward bending, walking, and medication)
Trial: 35367876
Drug: Naming treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naming treatment (modified semantic feature analysis)
Trial: 35367876
Drug: Non-naming treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-naming treatment (auditory comprehension, copying text, and reading)
Trial: 34228613
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg in 100 ml saline solution administered 20 minutes before the end of surgery
Trial: 34228613
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 100 ml saline solution without TXA
Trial: 33160931
Drug: Skin patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin patch test (SPT) with sodium lauryl sulfate, cocamidopropyl betaine, propylene glycol, aluminum chloride hexahydrate, menthol, triclosan, and titanium dioxide
Trial: 33160931
Drug: Skin patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin patch test (SPT)
Trial: 33046478
Drug: Multidisciplinary team‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary team‐based medication optimisation
Trial: 33879219
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - medical consultation alone
Trial: 34083331
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy with corresponding targeted drugs for patients with actionable alterations.
Trial: 34083331
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor treatment with sintilimab for patients without actionable alterations.
Trial: 34083331
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with sintilimab or atezolizumab after resistance to vemurafenib, niraparib, and palbociclib.
Trial: 34083331
Drug: Single-agent immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent immunotherapy (sintilimab) in the single-agent immunotherapy group.
Trial: 33449867
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of r-IPL and fractional CO2 laser
Trial: 33449867
Drug: Therapeutic standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic standard dose of the fractional CO2 laser
Trial: 35291025
Drug: Individualised STOPP/START-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised STOPP/START-based medication optimisation recommendations discussed with patients and physicians
Trial: 35291025
Drug: Individualised STOPP/START-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised STOPP/START-based medication optimisation recommendations
Trial: 32914161
Drug: Dexmedetomidine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.2 μg/kg
Trial: 32914161
Drug: Fentanyl 0.2
RxNorm normalized name: fentanyl 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.2 μg/kg
Trial: 32914161
Drug: Control (Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Bupivacaine 0.5% 2 mL)
Trial: 36215947
Drug: Trivalent ganglioside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821
Trial: 35414106
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg (control group)
Trial: 32798261
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg saffron daily for 12 weeks
Trial: 34051389
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HPV vaccine
Trial: 35279213
Drug: Rusk-like biscuit
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rusk-like biscuit powder with hen's egg (HE), cow’s milk (CM), peanut (PN), and hazelnut (HN) (initially approximately 2 mg of each food protein) for 6–8 months.
Trial: 35279213
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving rusk-like biscuit powder without HE, CM, PN, and HN on a daily basis.
Trial: 32438452
Drug: Eliglustat therapy
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat therapy
Trial: 33639045
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (100 mcg menaquinone-7) and vitamin D3 (10 mcg calcitriol)
Trial: 36190994
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg daily
Trial: 32909921
Drug: CPAP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP + OA (oral airway open)
Trial: 32909921
Drug: CPAP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP + OA (oral airway closed)
Trial: 32909921
Drug: CPAP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP + OA (oral airway open) and CPAP + OA (oral airway closed)
Trial: 39179982
Drug: Solution-Focused Brief
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution-Focused Brief Therapy (SFBT)
Trial: 32227713
Drug: Yun's optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yun's optimized pelvic floor training (OPFT) therapy for 6 weeks followed by 6 weeks of traditional pelvic floor muscle exercises (PFME)
Trial: 32227713
Drug: Traditional pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional pelvic floor muscle exercises (PFME) for 6 weeks followed by 6 weeks of Yun's OPFT therapy
Trial: 35026375
Drug: Favipiravir 1800
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir 1800 mg by mouth twice daily on day 1 followed by 800 mg twice daily for 5 to 7 days
Trial: 32250328
Drug: Conventional neurodevelopmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neurodevelopmental treatment (NDT)
Trial: 35342931
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment + aprotinin
Trial: 34514764
Drug: Combination program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination program including smartphone nutrition education, physical activity (aerobics exercise for 45 minutes three times per week), and cognitive behavioral therapy (CBT) sessions (8 sessions designed for children)
Trial: 32300382
Drug: Chemical blockage
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical blockage of celiac ganglions by ethanol injection
Trial: 35050348
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent nivolumab
Trial: 35050348
Drug: Combination nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination nivolumab and ipilimumab
Trial: 32676853
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for GI malignancy
Trial: 32676853
Drug: Pre-chemotherapy screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy screening
Trial: 32676853
Drug: Investigations for
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigations for chemotherapy-induced symptoms
Trial: 36428060
Drug: Online laughter
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online laughter therapy (twice weekly for four weeks)
Trial: 33715056
Drug: Cement applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cement applied on implant surfaces (group 2)
Trial: 33715056
Drug: Cement applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cement applied on both bone and implant surfaces (group 3)
Trial: 35812412
Drug: WIBP-CorV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WIBP-CorV vaccine (2.5, 5.0, and 10.0μg/dose)
Trial: 35812412
Drug: WIBP-CorV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WIBP-CorV vaccine
Trial: 33433260
Drug: Usual occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual occupational therapy exercises (Control)
Trial: 32998926
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg subcutaneous weekly until week 4, then at week 8; escalated to 300 mg subcutaneous every 4 weeks for non-responders at week 12; switched to adalimumab biosimilar 40 mg subcutaneous every 2 weeks for non-responders at week 24.
Trial: 32998926
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment at the discretion of the physician.
Trial: 32826001
Drug: Breathing retraining
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing retraining and four weekly manual therapy sessions (immediate start)
Trial: 32826001
Drug: Breathing retraining
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing retraining and four weekly manual therapy sessions (delayed start)
Trial: 34981467
Drug: Curcuminoids (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (500 mg/day)
Trial: 35331684
Drug: Nitroglycerin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (500 μg)
Trial: 33472541
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment effect estimation methods
Trial: 35982457
Drug: Dental Care
RxNorm normalized name: Arm And Hammer Dental Care Mint Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental Care Professionals (dental therapists and dental nurses) visiting care homes every 6 months and monthly for the first 3 months, then three-monthly thereafter
Trial: 33896224
Drug: Somatropin treatment
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Somatropin treatment
Trial: 35984704
Drug: CT900 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT900 at a dose of 12 mg/m2 every 2 weeks (q2Wk)
Trial: 34281849
Drug: Low-dose OSK-0028
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OSK-0028 (0.25 μg/kg/h)
Trial: 34281849
Drug: High-dose OSK-0028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose OSK-0028 (0.5 μg/kg/h)
Trial: 34281849
Drug: OSK-0028 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSK-0028 (both doses)
Trial: 36011519
Drug: Telemedicine‐delivered counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine‐delivered counseling and printed materials on diet and medication adherence
Trial: 34332557
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg/day monotherapy
Trial: 34332557
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with allogeneic CD8 + CD56+ NKT cell infusions twice per month for 12 cycles
Trial: 32228462
Drug: Couple-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based intervention arm (patients and spouses receive four-weekly structured group education & training sessions and 2 months of weekly tailored behavior change boosters)
Trial: 35906331
Drug: Higher-density formula
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-density formula (HDF, 90 kcal/100 ml)
Trial: 35906331
Drug: Standard-density formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-density formula (SDF, 67 kcal/100 ml)
Trial: 32672570
Drug: Pericardium patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericardium patch grafts
Trial: 32268801
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus exercise
Trial: 36090717
Drug: Tropocollagen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropocollagen gel applied to the skin around the wound
Trial: 36170500
Drug: Bionic pancreas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionic pancreas treatment with insulin aspart or insulin lispro
Trial: 36170500
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (any insulin-delivery method with unblinded, real-time continuous glucose monitoring)
Trial: 32401385
Drug: Dexlansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole 60 mg, once daily before breakfast for 8 weeks
Trial: 32401385
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, once daily before breakfast for 8 weeks
Trial: 33055188
Drug: High-dose eplerenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose eplerenone
Trial: 32921501
Drug: High-dose pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pitavastatin (4 mg/d)
Trial: 34121344
Drug: High-dose biologics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose biologics
Trial: 34642026
Drug: CP/ganitumab (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP/ganitumab (18 mg/kg q3w)
Trial: 33278625
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (12 mg once daily for 5 days)
Trial: 33278625
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin + doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days)
Trial: 34602110
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or Sertraline treatment for 6 weeks
Trial: 34602110
Drug: SSRIs (Fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (Fluoxetine or Sertraline)
Trial: 35699705
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg twice daily; n = 300)